Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients
Fred C. G. J. Sweep
The Journal of Clinical Endocrinology & Metabolism, 2009
View PDFchevron_right
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes
Anders Grubb
Journal of Internal Medicine, 2006
View PDFchevron_right
Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes
Supphamat Chirnaksorn
Cureus, 2021
View PDFchevron_right
Pioglitazone reduces monocyte activation in type 2 diabetes
Simona Giubilato, Filippo Crea
2009
View PDFchevron_right
Pioglitazone provides beneficial effect in metabolic syndrome rats via affecting intracellular Na+ Dyshomeostasis
Belma TURAN
Journal of Bioenergetics and Biomembranes, 2018
View PDFchevron_right
Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study
Angel rodriguez
Cardiovascular Diabetology, 2011
View PDFchevron_right
Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat
Arthur Swislocki
American Journal of Hypertension, 2000
View PDFchevron_right
Combined Therapy of Pioglitazone and Atorvastatin Alleviate Diabetes in Rats More Effectively than That of Mono Therapy
saiful Islam
Pharmacology & Pharmacy, 2014
View PDFchevron_right
Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
Adriana Monroy
The Journal of Clinical Endocrinology & Metabolism, 2010
View PDFchevron_right
Pioglitazone Reduces Hepatic Fat Content and Augments Splanchnic Glucose Uptake in Patients With Type 2 Diabetes
L. Hardies
Diabetes, 2003
View PDFchevron_right
Comparative evaluation of Pioglitazone versus Voglibose on glycemic control in patients with Type 2 Diabetes Mellitus on Metformin
Mohd Faheem Mubeen
Journal of Medical Science And clinical Research, 2018
View PDFchevron_right
Population Pharmacokinetics of Pioglitazone in South Indian Type-II Diabetic Patients
Devender Kodati
Asian Journal of Pharmaceutical and Clinical Research, 2014
View PDFchevron_right
Pioglitazone Acutely Reduces Energy Metabolism and Insulin Secretion in Rats
Élise Jalbert-Arsenault
Diabetes, 2013
View PDFchevron_right
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes
Thongchai Pratipanawatr
2003
View PDFchevron_right
Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes
Attila Brehm
Diabetes, Obesity and Metabolism, 2013
View PDFchevron_right
Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance
Eduardo Hernandez-Salazar
Diabetes Research and Clinical Practice, 2007
View PDFchevron_right
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome
Frank Greenway
Diabetes, Obesity and Metabolism, 2009
View PDFchevron_right
The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
farzad najafipour
Therapeutic Advances in Endocrinology and Metabolism, 2015
View PDFchevron_right
Effect of metformin and Pioglitazone on insulin dose reduction in type 2 diabetes mellitus patients: An open level comparative prospective study
Anindya Dasgupta
Journal of Diabetes Mellitus, 2012
View PDFchevron_right
Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
Bancha Satirapoj
PLOS ONE, 2018
View PDFchevron_right
Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes
Dhananjay gupta
Diabetes, 2019
View PDFchevron_right
Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis
Krassimir Kalinov
Diabetology & Metabolic Syndrome
View PDFchevron_right
Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects
Md. Aftab Uddin
Drug and Chemical Toxicology, 2013
View PDFchevron_right
Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin- sensitizing agent pioglitazone
Jerry Colca
Arteriosclerosis, Thrombosis, and Vascular Biology, 1993
View PDFchevron_right
Pioglitazone: A Review of its Use in Type 2 Diabetes Mellitus
John Waugh, Dean Robinson
Drugs, 2006
View PDFchevron_right
Spotlight on Pioglitazone in Type 2 Diabetes Mellitus1
Dean Robinson, John Waugh
Treatments in Endocrinology, 2006
View PDFchevron_right
Effects of Pioglitazone on Adipose Tissue Remodeling Within the Setting of Obesity and Insulin Resistance
D. Laurent
Diabetes, 2001
View PDFchevron_right
Pioglitazone Increases the Proportion of Small Cells in Human Abdominal Subcutaneous Adipose Tissue
Arthur Sherman
Obesity, 2010
View PDFchevron_right
Effect of Pioglitazone on Lipid Profile in Type 2 Diabetic Patients
MUHAMMAD BILAL
2012
View PDFchevron_right
Pioglitazone Improves Fat Distribution, the Adipokine Profile and Hepatic Insulin Sensitivity in Non-Diabetic End-Stage Renal Disease Subjects on Maintenance Dialysis: A Randomized Cross-Over Pilot Study
Luc Tappy
PLoS ONE, 2014
View PDFchevron_right
Effect of Pioglitazone on the Fructose-Induced Abdominal Adipose Tissue Dysfunction
Eduardo Spinedi
PPAR Research, 2012
View PDFchevron_right
Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes
André Grimaldi
Diabetes Research and Clinical Practice, 2009
View PDFchevron_right